Cor Therapeutics Integrilin
Sales of the GP IIb/IIIa antagonist totaled $63.7 mil. in 1999. The market Aclearly has a $1.5 bil. potential,@ CEO Vaughn Kailian maintained at Chase H&Q. Cor has identified growth opportunities for earlier usage in patients already being treated with Integrilin, as well as additional use in urgent patients. Currently 60% of Integrilin use is in patients undergoing elective procedures, and 40% is in urgent patients. Cor intends Ato ensure that we increase our penetration, increase our usage length of time, and increase our distribution in the US.@ Currently, out of 2,400 facilities where the product could potentially be used, Integrilin is Aprobably being used in half of those hospitals,@ Kailian said. Cor is planning to unblind a study on the use of Integrilin in the setting of angioplasty and stents during the 2nd quarter
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth